March 16, 2020, HOUSTON– Celltex Therapeutics Corporation, a Houston, Texas-based biotechnology company founded in 2011 and focused on spearheading breakthroughs in regenerative medicine using adult, autologous Mesenchymal Stem Cells (“MSCs”), today announced that it has begun active discussions with the FDA regarding a study using MSCs against Coronavirus (“COVID-19”)-type symptoms. [Read more…]
NIH clinical trial of investigational vaccine for COVID-19 underway in Seattle
A study enrolling Seattle-based healthy adult volunteers will test the vaccine mRNA-1273 developed by NIH scientists and their collaborators at Moderna, Inc.
Vitro Diagnostics’ Potential Stem Cell Therapy for Coronavirus Infection
GOLDEN, CO; February 27, 2020 — Vitro Diagnostics, Inc. (OTCPK:VODG), dba Vitro Biopharma, reports on a potential therapy of Coronavirus (COVID-19) infections by stem cell transplant. While this therapy is not a method to eradicate or cure Coronavirus, there is evidence to support the concept that infected patients may be more likely to combat and survive infection.
First, stem cells resist viral attack by the expression of certain genes known as interferon gamma stimulated genes (ISGs). These are expressed in stem cells prior to their differentiation. (Wu, X, et al, Cell 172: 423, 2018). Hence, stem cells would be expected to survive even if transplanted into a patient with an active Coronavirus infection. [Read more…]
Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease
NEW YORK, March 10, 2020 — Mesoblast Limited (Nasdaq: MESO; ASX:MSB) announced that it plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) in the United States, Australia, China and Europe. The Company is in active discussions with various government and regulatory authorities, medical institutions and pharmaceutical companies to implement these activities. [Read more…]
